EUCTR2010-022211-19-BE进行中（未招募）1 期
PILOT STUDY TO EXPLORE EFFICACY AND SAFETY OF DIFFERENT DOSE REGIMENS OF CD5789 IN SUBJECTS WITH ACNE VULGARIS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GALDERMA R&D
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •* Male or female subject aged from 18 to 35 years old
- •* The subject has medical diagnosis of moderate to severe acne vulgaris on the face
- •* The subject has, on the face, at least 20 inflammatory lesions and 30 non-inflammatory lesions
- •* The Subject has a severity grade of 3 or 4 on the Investigator’s Global Assessment (IGA) scale on either side of the face
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •* The subject has more than 2 acne nodules/cysts on the face
- •* The subject has severe forms of acne (acne conglobata, acne fulminans) or secondary acne form (chloracne, drug-induced acne, etc.)
- •* The number of inflammatory or non inflammatory lesions on half-face is greater than twice the number on the other half-face
研究者
相似试验
进行中（未招募）
不适用
PILOT STUDY TO EXPLORE EFFICACY AND SAFETY OF DIFFERENT DOSE REGIMENS OF CD5789 IN SUBJECTS WITH ACNE VULGARISAcne vulgarisMedDRA version: 12.1Level: LLTClassification code 10000519Term: Acne vulgarisEUCTR2010-022211-19-HUGALDERMA R&D120
进行中（未招募）
不适用
PILOT STUDY TO EXPLORE EFFICACY AND SAFETY OF DIFFERENT DOSE REGIMENS OF CD5789 IN SUBJECTS WITH ACNE VULGARISAcne vulgarisMedDRA version: 12.1Level: LLTClassification code 10000519Term: Acne vulgarisEUCTR2010-022211-19-DEGALDERMA R&D120
进行中（未招募）
1 期
PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SWITCHING PROTEASE INHIBITOR TO ETRAVIRINE IN HIV-1-INFECTED SUBJECTS WITH VIREMIA SUPPRESSION (ESTUDIO PILOTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LA SIMPLIFICACIÓN DE UN INHIBIDOR DE LA PROTEASA A ETRAVIRINA EN PACIENTES CON INFECCIÓN POR EL VIH-1 EN SUPRESIÓN VIRAL)Infección por el VIH.MedDRA version: 9Level: LLTClassification code 10008919Term: Chronic HIV infectionEUCTR2009-016455-21-ESFundació Lluita contra la SIDA
尚未招募
不适用
Searching new Antidote for old deadly celphos poisoningCTRI/2021/06/034004Intra Mural sponsoring body of PGIMER
进行中（未招募）
不适用
A randomized pilot study comparing the safety of DAbigatran and RIvaroxaban versus NAdroparin in the prevention of venous thromboembolism after knee arthroplasty surgery. DARINAAfter total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE). Two novel agents, dabigatran and rivaroxaban, recently gained market authorisation for prevention of venous thromboembolism after knee arthroplasty.Our aim is to compare the long term use of dabigatran and rivaroxaban versus nadroparin on safety after total knee arthroplasty (TKA)EUCTR2011-003556-39-NLMartini Hospital Groningen